Transfer from: financial sector
Source of this article: financial circles
On June 12, Harbin Pharmaceutical Co., Ltd Obtained Cinda Securities Buying rating, Harbin Pharmaceutical Co., Ltd. won the attention of one research paper in the past month. According to the research report, the operating revenue of the company in 2024-2026 will be 16.89 billion yuan, 18.574 billion yuan and 20.686 billion yuan respectively, with year-on-year growth rates of about 9%, 10% and 11% respectively. The net profit attributable to the parent company will be 468 million yuan, 621 million yuan and 838 million yuan, with year-on-year growth rates of 19%, 33% and 35% respectively. The research report believes that the core investment logic: "marketing system remodeling+brand product volume+cost control" promotes the high growth of industrial business profits, industrial gross profit margin is expected to show a trend of increasing year by year, and the cost rate side is expected to continue to optimize during the period. In 2023, the revenue of industrial business will account for about 33%, and GNC business will grow rapidly. Profit forecast and investment rating: we give the company a "buy" investment rating.
Risk tip: market competition intensifies, marketing system optimization and sales are less than expected, quality and efficiency improvement progress is less than expected, pharmaceutical wholesale business growth is less than expected, and accounts receivable recovery is not timely.
MACD Golden Cross signal is formed, and these stocks are rising well!
Massive information, accurate interpretation, all in Sina Finance APP
